Sign in
CompletedNo phase

Atropine Alone vs Atropine Plus Bifocal Spectacles for Myopia Control in Children

Key facts

Who runs it
University of Faisalabad
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
210 people enrolled
Started
17 Feb 2025
Ended
15 May 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Atropine Sulfate 0.05% Ophthalmic Solution
  • Bifocal Spectacles
Record updated
29 May 2026

Who can take part

Age
4 years to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Children aged 4 to 16 years
  • Bilateral myopia with cycloplegic spherical equivalent refraction between -1.00 D and -6.00 D in each eye
  • Documented recent myopia progression of ≥ -0.50 D over the preceding 12 months
  • Best-corrected visual acuity (BCVA) of at least 6/12 (Snellen) or equivalent in each eye
  • Parent or guardian able and willing to provide written informed consent
  • Child assent when applicable (age 7 years and above per institutional policy)

Who cannot take part

  • Prior myopia-control treatment within 6 months (atropine, orthokeratology, multifocal contact lenses, pirenzepine)
  • Ocular conditions affecting myopia progression: strabismus, amblyopia, significant astigmatism (>2.50 D), anisometropia (>2.50 D), cataract, glaucoma, uveitis, or history of ocular surgery
  • Known allergy or hypersensitivity to atropine or spectacle materials
  • Systemic or neurodevelopmental disorders affecting cooperation or refractive development
  • Inability to obtain accurate axial length or cycloplegic refraction measurements
  • Parent or guardian refusal to provide informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background: Myopia (nearsightedness) is a growing global health concern, projected to affect 50% of the world population by 2050. Children with progressive myopia are at risk of serious ocular complications including myopic maculopathy, glaucoma, and retinal detachment. Low-dose atropine (0.05%) has shown efficacy in slowing myopia progression, and optical interventions such as bifocal spectacles may provide additional benefits by altering peripheral retinal defocus. Objective: This randomized controlled trial aims to compare the efficacy and effectiveness of atropine 0.05% monotherapy versus combination therapy (atropine 0.05% plus bifocal spectacles) in controlling myopia progression in children. Methods: Children aged 4-16 years with bilateral myopia (cycloplegic spherical equivalent between -1.00 D and -6.00 D) and documented recent progression (≥ -0.50 D in the preceding 12 months) will be randomized 1:1 to receive either atropine 0.05% eye drops once daily or atropine 0.05% plus bifocal spectacles. The primary outcome is change in spherical equivalent refraction over 12 months; the secondary outcome is change in axial length. Follow-up visits occur at 3, 6, 9, and 12 months. Conclusion: This study will provide evidence on whether adding bifocal correction to pharmacological therapy offers superior myopia control compared to atropine alone, informing clinical practice guidelines for pediatric myopia management.

The 2 groups in the trial

  • Atropine 0.05% MonotherapyExisting treatment, for comparison

    Participants receive atropine sulfate 0.05% ophthalmic solution, one drop in each eye once daily at bedtime, for 12 months.

    Treatment: Atropine Sulfate 0.05% Ophthalmic Solution

  • Combination Therapy (Atropine 0.05% + Bifocal Spectacles)Treatment being tested

    Participants receive atropine sulfate 0.05% ophthalmic solution (same regimen as Arm A) PLUS bifocal spectacle correction with distance correction based on cycloplegic refraction and +2.00 D near addition. Spectacles are to be worn during all waking hours.

    Treatment: Bifocal Spectacles

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigating Comparative Efficacy of Myopia Control Strategies and Genetic Underpinnings: A Randomized Controlled Trial
Record updated
29 May 2026